What type of study is this?

This is a Quantitative Study study.

October 17, 2025Open Access

Supplementary Figure S3 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy

Key Points

Higher levels of clonal hematopoiesis and ferritin predict increased risks of hematologic toxicity.
Patients with elevated ferritin levels showed reduced overall survival and progression-free survival, impacting treatment decisions.
Analysis utilized survival data to assess outcomes, with notable hazard ratios indicating these risks.
Findings may guide monitoring and treatment strategies for patients undergoing B-cell maturation antigen-directed CAR T-cell therapy.

Abstract

Figure S3. (A-B) Progression-free survival (A) and overall survival (B) stratified by baseline ferritin (ferr.) and clonal hematopoiesis (CH), with estimated median and/or 24-month survival and hazard ratios (HR) with 95% confidence intervals (CI) shown. NR, not reached.

Supplementary Figure S3 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy

Key Points

Abstract

Cite This Study

Also Consider

Also Consider